Sun Pharmaceuticals receives approval for Winlevi in Australia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Subscribe To Our Newsletter & Stay Updated